The treatment of ulcerative colitis with balsalazide sodium

Balsalazide sodium (5-aminosalicylic acid [5-ASA] linked to 4-aminobenzyl-β-alanine) was designed to deliver 5-ASA to the colonie mucosa without the sulphapyridine-associated side-effects seen with sulphasalazine. Studies amounting to some 450 patient-years exposure to balsalazide in patients with ulcerative colitis have so far confirmed the expectation of higher efficacy and high patient tolerance of balsalazide.